Sonoma pharmaceuticals highlights safety advantages of its microcyn products in light of growing concerns of benzene in many other topicals

Boulder, co / accesswire / march 27, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products. recently, there have been concerns that popular dermatology products can form benzene, a known carcinogen.
SNOA Ratings Summary
SNOA Quant Ranking